abstract |
These are proteins with variable domains of light chain and antibody heavy chain that can be paired to form an antigen binding site that targets CD33 (Siglec-3) in a cell, pharmaceutical compositions that comprise such proteins, and therapeutic methods that use such proteins and pharmaceutical compositions, including for the treatment of cancer. |